Literature DB >> 19414786

Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.

Yael Michaeli1, Galit Denkberg, Keren Sinik, Liz Lantzy, Chiang Chih-Sheng, Celine Beauverd, Tamar Ziv, Pedro Romero, Yoram Reiter.   

Abstract

Peptide Ags presented by class I MHC molecules on human melanomas and that are recognized by CD8(+) T cells are the subjects of many studies of antitumor immunity and represent attractive candidates for therapeutic approaches. However, no direct quantitative measurements exist to reveal their expression hierarchy on the cell surface. Using novel recombinant Abs which bind these Ags with a peptide-specific, MHC-restricted manner, we demonstrate a defined pattern of expression hierarchy of peptide-HLA-A2 complexes derived from three major differentiation Ags: gp100, Melan-A/Mart-1, and tyrosinase. Studying melanoma cell lines derived from multiple patients, we reveal a surprisingly high level of presentation of tyrosinase-derived complexes and moderate to very low expression of complexes derived from other Ags. No correlation between Ag presentation and mRNA expression was found; however, protein stability may play a major role. These results provide new insights into the characteristics of Ag presentation and are particularly important when such targets are being considered for immunotherapy. These results may shed new light on relationships between Ag presentation and immune response to cancer Ags.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414786     DOI: 10.4049/jimmunol.0801898

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  MHC class I antigen processing distinguishes endogenous antigens based on their translation from cellular vs. viral mRNA.

Authors:  Brian P Dolan; Aditi A Sharma; James S Gibbs; Tshaka J Cunningham; Jack R Bennink; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

Review 2.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

Review 3.  Properties and applications of single-chain major histocompatibility complex class I molecules.

Authors:  Eleni Kotsiou; Joanna Brzostek; Keith G Gould
Journal:  Antioxid Redox Signal       Date:  2011-03-31       Impact factor: 8.401

4.  Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.

Authors:  Christopher J Holland; Rory M Crean; Johanne M Pentier; Ben de Wet; Angharad Lloyd; Velupillai Srikannathasan; Nikolai Lissin; Katy A Lloyd; Thomas H Blicher; Paul J Conroy; Miriam Hock; Robert J Pengelly; Thomas E Spinner; Brian Cameron; Elizabeth A Potter; Anitha Jeyanthan; Peter E Molloy; Malkit Sami; Milos Aleksic; Nathaniel Liddy; Ross A Robinson; Stephen Harper; Marco Lepore; Chris R Pudney; Marc W van der Kamp; Pierre J Rizkallah; Bent K Jakobsen; Annelise Vuidepot; David K Cole
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

5.  TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms.

Authors:  Oleg Y Borbulevych; Sujatha M Santhanagopolan; Moushumi Hossain; Brian M Baker
Journal:  J Immunol       Date:  2011-07-27       Impact factor: 5.422

6.  TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes.

Authors:  Rony Dahan; Moran Tabul; Yuan K Chou; Roberto Meza-Romero; Shayne Andrew; Adolph J Ferro; Gregory G Burrows; Halina Offner; Arthur A Vandenbark; Yoram Reiter
Journal:  Eur J Immunol       Date:  2011-04-12       Impact factor: 5.532

7.  Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.

Authors:  Douglas J Hanlon; Paulomi B Aldo; Lesley Devine; Ayesha B Alvero; Anna K Engberg; Richard Edelson; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2011-01-18       Impact factor: 3.886

8.  Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.

Authors:  Tomohide Tsukahara; Makoto Emori; Kenji Murata; Takahisa Hirano; Norihiro Muroi; Masanori Kyono; Shingo Toji; Kazue Watanabe; Toshihiko Torigoe; Vitaly Kochin; Hiroko Asanuma; Hiroshi Matsumiya; Keiji Yamashita; Tetsuo Himi; Shingo Ichimiya; Takuro Wada; Toshihiko Yamashita; Tadashi Hasegawa; Noriyuki Sato
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

Review 9.  Opportunities and challenges for TCR mimic antibodies in cancer therapy.

Authors:  Aaron Y Chang; Ron S Gejman; Elliott J Brea; Claire Y Oh; Melissa D Mathias; Dmitry Pankov; Emily Casey; Tao Dao; David A Scheinberg
Journal:  Expert Opin Biol Ther       Date:  2016-04-27       Impact factor: 4.388

10.  Specific increase in potency via structure-based design of a TCR.

Authors:  Karolina Malecek; Arsen Grigoryan; Shi Zhong; Wei Jun Gu; Laura A Johnson; Steven A Rosenberg; Timothy Cardozo; Michelle Krogsgaard
Journal:  J Immunol       Date:  2014-07-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.